T. Rowe Price
Global asset manager offering retirement solutions
Chief of Staff - Global Investments
+ Bonus
Hybrid work schedule; consistent in-office presence is aligned with leadership needs.
About the job
- Well-established internal network across Investments, Distribution, and enterprise functions.
- Proven ability to navigate and influence across multiple groups quickly.
- Credibility to represent the Co-Heads of Global Investments with senior leaders immediately.
- Demonstrated ability to assess and elevate executive-level materials.
- Experience with strategy development, executive presentations, and/or client engagement.
- Ability to translate complex work into clear, decision-ready narratives.
- Proven ability to influence without direct authority.
- Strong presence and confidence engaging with senior stakeholders.
- Trusted advisor who can challenge constructively and improve outcomes.
- Ability to operate at high pace with shifting priorities.
- High level of availability, responsiveness, and consistent in-office presence aligned with leadership needs.
- Flexibility to support intensive periods of work, including nights and weekends when needed.
- Strong understanding of the Investments business and operating model.
- Represent the Co-Heads of Global Investments with senior leaders across Investments and the firm, including Management Committee members, Risk, Audit, Human Resources, and Enterprise Change.
- Maintain strong, trust-based relationships across a wide internal network.
- Serve as a connector and influencer, ensuring alignment and surfacing issues quickly.
- Act as a proxy where appropriate, ensuring messaging and positioning are consistent with the Co-Heads of Global Investments’ perspective.
- Participate in key cross-functional initiatives and steering committees.
- Bring a strategic enterprise view by connecting dots across functions and investment teams.
- Influence without authority to drive alignment, resolve issues, and accelerate progress.
- Prepare concise, decision-oriented briefings for the Co-Heads of Global Investments.
- Shape agendas and content for leadership meetings, including investment leadership forums.
- Ensure discussions are focused, decision-oriented, and well-prepared.
- Coordinate input while leveraging existing resources for administrative execution.
- Organize preparation and distribution of materials in partnership with the Senior Executive Assistant.
- Act as a quality-control checkpoint for presentations, strategy updates, and executive communications before they reach senior forums.
- Evaluate whether work is ready for the Co-Heads of Global Investments, aligned to the strategic narrative and investment priorities, and clear, concise, and appropriate for executive or client audiences.
- Leverage experience with executive presentations and/or client engagement to raise the overall quality bar.
- Provide direct, actionable feedback to teams on how to improve content.
- Prioritize and manage the Co-Heads of Global Investments’ calendars with a sharp focus on the highest-value engagements.
- Manage requests to ensure all meetings and commitments have a clear purpose, outcomes, and preparation.
- Coordinate internal and external events while balancing associate, client, and other external audience needs and ensuring efficient use of travel time.
- Provide insightful pre-reads and briefings, including context on participants, sensitivities, and decision points.
- Optimize travel and engagements to balance clients, internal leadership, and enterprise priorities.
- CFA or equivalent investment expertise is a plus, though it is additive rather than required.
- Client-facing experience, especially for external engagement context, is highly valued.
About the company
T. Rowe Price provides investment management and retirement solutions to individual investors, financial intermediaries, and institutions worldwide. It manages client assets through a disciplined, research-driven investment process and offers a range of strategies and products designed for long-term value. Clients pay management fees based on assets under management, with total assets under management around $1.569 trillion as of June 30, 2024. The company differentiates itself by its global research capabilities, experienced investment teams, and broad client base, enabling tailored solutions for personal accounts, retirement plans, and institutional clients. Its goal is to help clients reach their financial objectives by growing and preserving capital over the long term through diversified investment strategies.
Company Size
10,001+
Company Stage
IPO
Headquarters
Baltimore, Maryland
Founded
1937
Get referred to T. Rowe Price
See people who can refer or advise you
Simplify's Take
What believers are saying
- T. Rowe Price launched eight active ETFs in 2026, broadening product distribution.
- Anthropic's Claude now supports portfolio managers, analysts, and developers across the investment process.
- F/m Investments closes in early 2027, lifting fixed-income AUM and ETF capabilities.
What critics are saying
- August 2026 net outflows hit $7.9 billion, extending persistent client redemptions.
- The Q2 2026 severance charge signals ongoing expense cuts and organizational strain.
- Passive ETFs and low-fee private-market funds compress margins, threatening long-term earnings power.
What makes T. Rowe Price unique
- T. Rowe Price managed $1.90 trillion as of August 31, 2026.
- Two-thirds of assets are retirement-related, anchoring durable fee flows.
- The Goldman Sachs private-markets alliance expands access across private equity, credit, real estate.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Paid Volunteer Time
Parental Leave
Learning & Growth Resources
Matching Charitable Gifts
Health Care Benefits
Generous Retirement Plan
Company News
Capital to accelerate the buildout of rare earth production infrastructure across the United States, advancing Cyclic Materials' proprietary platform to strengthen domestic recovery and supply of critical materials.
Five entities sold an 11.05% stake in Sedemac Mechatronics for ₹1,468.83 crore, while domestic and foreign institutional investors bought shares.
Teamshares has secured a $225 million preferred equity investment from accounts advised by T. Rowe Price Investment Management. The funding is structured as Series A perpetual, non-voting, non-convertible preferred stock. The company intends to use the proceeds primarily for acquisitions, central to its programmatic growth strategy. The investment includes an option to raise an additional $75 million from other institutional investors. The preferred stock carries a 16% annual dividend rate if paid in cash, stepping down to 14.5% upon meeting specified deleveraging and EBITDA thresholds. The instrument is callable at any time, subject to make-whole provisions through the second anniversary, and holders may require redemption beginning on the seventh anniversary. CEO Michael Brown noted the company has over 15,000 size-qualified, actively-for-sale companies annually through its software. Teamshares operates subsidiaries with consolidated revenue exceeding $500 million for the trailing twelve months as of 30 June 2026. Goldman Sachs served as exclusive financial advisor on the transaction.
Enveda, an AI drugmaker, banks $311M in venture funding. Enveda, which is using AI tools to mine plants and microbes for drug prospects, has three candidates in human testing for immune diseases and obesity. Published Sept. 23, 2026 Colorado-based AI drug discovery specialist Enveda Biosciences has raised $311 million in a Series E financing, a sum rivaling totals secured in some of the biotechnology sector's larger initial public offerings this year. In a Wednesday announcement, the startup said it would use the cash to continue advancing its pipeline of drugs through the clinic. Three are in human testing. Enveda uses artificial intelligence to identify molecules in living organisms like plants and microbes and predict their structure and function. Its system then ranks these molecules by their drug potential, after which Enveda's chemists turn the most promising ones into drug prospects. In June, Enveda CEO and founder Viswa Colluru told BioPharma Dive that the company is already evaluating 17 programs to emerge from that research. "As much as the industry has gotten comfortable with the more iterative approaches, the thing that moves the needle for patients and seeds power law returns for companies is first-in-class mechanisms that shift the paradigm," Colluru said at the time. Earlier this year, Enveda revealed Phase 1 data from a pair of AI-designed programs for atopic dermatitis and obesity. One of those programs, ENV-294, is a "molecular glue" that showed the potential to reduce eczema symptoms in a small, early clinical trial. Colluru said that Enveda's drug, a pill, could help people who don't respond to approved atopic dermatitis treatments like Dupixent. Phase 2 trials are underway in eczema and asthma. Alongside that drug is ENV-308, which Enveda has billed as a "pill designed from the chemistry of exercise." That experimental therapy mimics a hormone, "Lac-Phe," the body releases after exercise or meals, and displayed an encouraging safety profile in early-stage testing. The company plans to test ENV-308's ability to help people maintain weight loss after stopping GLP-1 use. A third drug, ENV-6949, targets the TL1A pathway, a popular and emerging approach to treat inflammatory bowel disease. "The way we think about it is, put multiple drugs into the clinic [and] strategically partner each of these at the time when the value inflection is right, such that we get both the validation and capital to move other chess pieces further along," Colluru said in June. Enveda's Series E round was led by Catalio Capital Management and includes 16 other backers, among them Surveyor Capital, T. Rowe Price, Lux Capital and a sovereign wealth fund. The company previously banked more than $530 million in venture backing, including a $150 million Series D round in 2025.
AI research and products that put safety at the frontier.